


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5265481/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<scp>TIM3</scp> / <scp>CEACAM1</scp> pathway involves in myeloidâ€derived suppressor cells induced <scp>CD8</scp> ⁺ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome. Immunology, 2023, 168, 273-289.	2.0	12
2	Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma. Cytometry Part B - Clinical Cytometry, 2022, 102, 44-49.	0.7	3
3	Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. Age and Ageing, 2022, 51, .	0.7	7
4	SUZ12 participates in the proliferation of PNH clones by regulating histone H3K27me3 levels. Journal of Leukocyte Biology, 2022, 112, 243-255.	1.5	2
5	A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis. Experimental Hematology and Oncology, 2022, 11, 1.	2.0	3
6	Clinical observation of lowâ€dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A singleâ€center retrospective analysis. Journal of Clinical Laboratory Analysis, 2022, 36, e24239.	0.9	2
7	Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease. Journal of Investigative Medicine, 2022, , jim-2021-002192.	0.7	2
8	Abnormal expression of histone acetylases in CD8+ T cells of patients with severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2022, 36, e24339.	0.9	4
9	Identification of potential pathogenic genes for severe aplastic anemia by wholeâ€exome sequencing. Journal of Clinical Laboratory Analysis, 2022, 36, e24438.	0.9	2
10	New Trends of Nontransplant therapy for Acquired Aplastic Anemia. Current Pharmaceutical Design, 2022, 28, .	0.9	1
11	Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-21.	1.9	2
12	Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia. Disease Markers, 2022, 2022, 1-10.	0.6	0
13	Ferritin Light Chain: A Candidate Autoantigen in Immuno-Related Pancytopenia. Frontiers in Immunology, 2022, 13, 851096.	2.2	0
14	Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. Investigational New Drugs, 2022, 40, 738-746.	1.2	1
15	Tumorâ€associated macrophages regulate the function of cytotoxic T lymphocyte through <scp>PD</scp> â€1/ <scp>PDâ€L1</scp> pathway in multiple myeloma. Cancer Medicine, 2022, 11, 4838-4848.	1.3	7
16	Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway. Leukemia and Lymphoma, 2021, 62, 218-223.	0.6	19
17	Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2021, 35, e23667.	0.9	4
18	Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 949-954.	1.3	5

#	Article	IF	CITATIONS
19	Upregulated expression of leukocyte immunoglobulin‑like receptorÂA3 in patients with severe aplastic anemia. Experimental and Therapeutic Medicine, 2021, 21, 346.	0.8	4
20	Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. Clinical and Experimental Immunology, 2021, 205, 53-62.	1.1	14
21	Current research status of HLA in immuneâ€related diseases. Immunity, Inflammation and Disease, 2021, 9, 340-350.	1.3	35
22	The Role of IncRNA AF117829.1 in the Immunological Pathogenesis of Severe Aplastic Anaemia. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-19.	1.9	1
23	Long Non-coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients. Turkish Journal of Haematology, 2021, 38, 236-238.	0.2	Ο
24	Expression and function of SLAMF6 in CD8+ T lymphocytes of patients with severe aplastic anemia. Cellular Immunology, 2021, 364, 104343.	1.4	5
25	Upregulated Expression of Profilin1 on Dendritic Cells in Patients With Severe Aplastic Anemia. Frontiers in Immunology, 2021, 12, 631954.	2.2	5
26	Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China. Leukemia and Lymphoma, 2021, 62, 2657-2664.	0.6	8
27	Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. Journal of Clinical Laboratory Analysis, 2021, 35, e23922.	0.9	7
28	lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	1.9	3
29	Plasma Metabolomic and Intestinal Microbial Analyses of Patients With Severe Aplastic Anemia. Frontiers in Cell and Developmental Biology, 2021, 9, 669887.	1.8	5
30	Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma. Cancer Biology and Medicine, 2021, 18, 721-733.	1.4	5
31	Single wholeâ€genome sequencing analysis of metastatic biopsy is sufficient for investigational treatment opportunities in cancer. Cancer Communications, 2021, , .	3.7	2
32	Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients. Blood, 2021, 138, 4783-4783.	0.6	0
33	Pyruvate Kinase M2 Regulates Hif-1alpha Activity in Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. Blood, 2021, 138, 1109-1109.	0.6	1
34	Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China. Blood, 2021, 138, 4728-4728.	0.6	0
35	Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China. Blood, 2021, 138, 4766-4766.	0.6	0
36	Role of EZH2 in Bone Marrow Mesenchymal Stem Cells and Immune–Cancer Interactions. Critical Reviews in Oncology/Hematology, 2021, 169, 103547.	2.0	4

#	Article	IF	CITATIONS
37	The Role of TLR4 Inducing Macrophage Pyroptosis in the Pathogenesis of Severe Aplastic Anemia. Blood, 2021, 138, 1114-1114.	0.6	0
38	SUZ12 Participates in PNH Cloning Proliferation By Regulating Histone H3K27me3 Methylation Level. Blood, 2021, 138, 1106-1106.	0.6	0
39	BMSCs Regulate the Function of NK Cell By CD155/Tigit/CD226 Pathway in MDS Patients. Blood, 2021, 138, 4651-4651.	0.6	1
40	Study of Bone Marrow Mesenchymal Stem Cells Regulating NK Cells Function through Tigit/ CD226 in Patients with Multiple Myeloma. Blood, 2021, 138, 2685-2685.	0.6	0
41	Role and Function of T Cell-Derived Exosomes and Their Therapeutic Value. Mediators of Inflammation, 2021, 2021, 1-7.	1.4	14
42	Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China. Hematology, 2021, 26, 874-880.	0.7	2
43	Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation–related apoptosis. Journal of Investigative Medicine, 2021, , jim-2021-002147.	0.7	0
44	Pseudo-monoclonal gammopathy due to autoimmune disease: a case report. Journal of International Medical Research, 2020, 48, 030006051986661.	0.4	0
45	Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. Journal of Clinical Laboratory Analysis, 2020, 34, e23008.	0.9	14
46	Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis. Journal of Clinical Laboratory Analysis, 2020, 34, e23057.	0.9	4
47	CD8 ⁺ T cells exhaustion induced by myeloidâ€derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Galâ€9 pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 1046-1058.	1.6	43
48	CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3 β /cyclinD1 signal pathway in Myeloma Bone Disease. Cancer Medicine, 2020, 9, 737-744.	1.3	11
49	Multiple Myeloma-Derived Exosomes Inhibit Osteoblastic Differentiation and Improve IL-6 Secretion of BMSCs from Multiple Myeloma. Journal of Investigative Medicine, 2020, 68, 45-51.	0.7	37
50	Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways. Frontiers in Oncology, 2020, 10, 584530.	1.3	9
51	Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. Frontiers in Oncology, 2020, 10, 1595.	1.3	33
52	Research Progress on NK Cell Receptors and Their Signaling Pathways. Mediators of Inflammation, 2020, 2020, 1-14.	1.4	48
53	Infection risk in autoimmune hematological disorders with lowâ€dose rituximab treatment. Journal of Clinical Laboratory Analysis, 2020, 34, e23455.	0.9	4
54	Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes. Innate Immunity, 2020, 26, 703-715.	1.1	9

#	Article	lF	CITATIONS
55	<p>Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China</p> . Cancer Management and Research, 2020, Volume 12, 8935-8941.	0.9	4
56	Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/β-Catenin Pathway. Stem Cells International, 2020, 2020, 1-16.	1.2	9
57	The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure. Journal of Immunology Research, 2020, 2020, 1-10.	0.9	1
58	Th9 Cells in Peripheral Blood Increased in Patients with Immune-Related Pancytopenia. Journal of Immunology Research, 2020, 2020, 1-8.	0.9	4
59	Effects of Epstein-Barr Virus Infection on CD19+ B Lymphocytes in Patients with Immunorelated Pancytopenia. Journal of Immunology Research, 2020, 2020, 1-9.	0.9	2
60	Proteomics analysis reveals alterations of NK cells in patients with severe aplastic anemia. International Journal of Laboratory Hematology, 2020, 42, 308-315.	0.7	5
61	Bone Marrow Plasma Cytokine Signature Profiles in Severe Aplastic Anemia. BioMed Research International, 2020, 2020, 1-11.	0.9	8
62	Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes. Frontiers in Oncology, 2020, 10, 962.	1.3	1
63	CTLAâ€4 and HLAâ€DQ are key molecules in the regulation of mDCâ€mediated cellular immunity by Tregs in severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2020, 34, e23443.	0.9	9
64	Effects of Shikonin on the Functions of Myeloid Dendritic Cells in a Mouse Model of Severe Aplastic Anemia. Mediators of Inflammation, 2020, 2020, 1-10.	1.4	6
65	Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma. International Journal of Molecular Medicine, 2020, 45, 1112-1120.	1.8	9
66	Antibodies specific to ferritin light chain polypeptide are frequently detected in patients with immune‑related pancytopenia. Molecular Medicine Reports, 2020, 22, 2012-2020.	1.1	5
67	Involvement of MM cell‑derived exosomes in T lymphocytes immune responses. Oncology Letters, 2020, 20, 31.	0.8	9
68	Bone Marrow-Derived Mesenchymal Stem Cells Inhibit CD8+ t Cell Immune Responses Via PD-1/PD-L1 Pathway in Multiple Myeloma. Blood, 2020, 136, 53-54.	0.6	0
69	Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals. Blood, 2020, 136, 5-6.	0.6	0
70	Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study. Blood, 2020, 136, 38-39.	0.6	0
71	The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure. Blood, 2020, 136, 10-11.	0.6	0
72	The Study of Proliferation Relative Long Non-Coding RNA FAM157C in CD59- cell from Paroxysmal Nocturnal Hemoglobinuria Patients. Blood, 2020, 136, 33-34.	0.6	0

#	Article	IF	CITATIONS
73	The short-term effect of histone deacetylase�inhibitors, chidamide and valproic acid, on�the�NF‴κB� in multiple myeloma cells. International Journal of Molecular Medicine, 2019, 43, 285-293.	pathway	6
74	Expression of C1q in the serum of patients with non‑severe aplastic anemia, and its association with disease severity. Molecular Medicine Reports, 2019, 19, 1194-1202.	1.1	1
75	Everolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway. Journal of Investigative Medicine, 2019, 67, 39-47.	0.7	10
76	Abnormal expression and mutation of the RBPJ gene may be involved in CD59‑ clonal proliferation in paroxysmal nocturnal hemoglobinuria. Experimental and Therapeutic Medicine, 2019, 17, 4536-4546.	0.8	8
77	High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1â€Î± signaling pathway. Oncology Letters, 2019, 17, 5395-5402.	0.8	4
78	Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function. Journal of Clinical Laboratory Analysis, 2019, 33, e22888.	0.9	11
79	Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis. Journal of Investigative Medicine, 2019, 67, 1067-1075.	0.7	9
80	Gene mutations associated with thrombosis detected by wholeâ€exome sequencing in paroxysmal nocturnal hemoglobinuria. International Journal of Laboratory Hematology, 2019, 41, 424-432.	0.7	6
81	CD56 ^{bright} natural killer cells exhibit abnormal phenotype and function in severe aplastic anemia. International Journal of Laboratory Hematology, 2019, 41, 353-363.	0.7	3
82	Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome. Journal of Investigative Medicine, 2019, 67, 1125-1130.	0.7	6
83	NK cells suppress CD8+ T cell immunity via NKG2D in severe aplastic anemia. Cellular Immunology, 2019, 335, 6-14.	1.4	16
84	The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia. Blood, 2019, 134, 3747-3747.	0.6	2
85	Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from MDS Patients and Promotes Leukemia Transformation. Blood, 2019, 134, 5398-5398.	0.6	1
86	Availability of NK cell expansion agent combined with recombinant IL‑2 and IL‑15 stimulation on the expansion and high‑purity of NK cells in patients with immune‑related pancytopenia in�vitro. Molecular Medicine Reports, 2019, 20, 4358-4366.	1.1	3
87	Abnormal numbers of CD4+ T lymphocytes and abnormal expression of CD4+ T lymphocyte‑secreted cytokines in patients with immune‑related haemocytopenia. Molecular Medicine Reports, 2019, 20, 3979-3990.	1.1	2
88	The Effect of Pyruvate Kinase M2: Inhibitor(shikonin) on the Function of Mdc in Severe Aplastic Anemia Mouse Model. Blood, 2019, 134, 5021-5021.	0.6	0
89	Adiponectin Inhibits the Differentiation and Maturation of Osteoclasts Via mTOR Pathway in Multiple Myeloma. Blood, 2019, 134, 5521-5521.	0.6	0
90	Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma. Blood, 2019, 134, 4416-4416.	0.6	0

#	Article	IF	CITATIONS
91	The Study of Proliferation Relative Long Non-Coding RNA in CD59- Cell from Paroxysmalnocturnal Hemoglobinuria Patients. Blood, 2019, 134, 5023-5023.	0.6	0
92	Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study. Blood, 2019, 134, 5493-5493.	0.6	1
93	The shortening telomere length of T lymphocytes maybe associated with hyper‑function in servere aplastic anemia. Molecular Medicine Reports, 2018, 17, 1015-1021.	1.1	8
94	Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes. Leukemia Research, 2018, 67, 12-16.	0.4	11
95	The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 216-226.	0.3	10
96	Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway. Oncology Letters, 2018, 15, 4079-4086.	0.8	17
97	Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes. Oncology Letters, 2018, 15, 5497-5504.	0.8	11
98	The Risk of Clonal Evolution of Granulocyte Colony-Stimulating Factor for Acquired Aplastic Anemia: A Systematic Review and Meta-Analysis. Acta Haematologica, 2018, 140, 141-145.	0.7	5
99	Abnormal changes in the quantity and function of osteoblasts cultured in�vitro in patients with myelodysplastic syndrome. Oncology Letters, 2018, 16, 4384-4390.	0.8	2
100	The clinical characteristics and therapy response of patients with acquired pure red cell aplasia. Hematology, 2018, 23, 639-645.	0.7	11
101	Epstein Barr Virus Infection Affects Function of Cytotoxic T Lymphocytes in Patients with Severe Aplastic Anemia. BioMed Research International, 2018, 2018, 1-10.	0.9	5
102	PKM2 Is Required to Activate Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-9.	1.9	14
103	MM-derived exosomes can promote apoptosis and inhibit proliferation of HD-CD4+T, inhibit apoptosis and promote proliferation but inhibit perforin secretion of HD-CD8+T, inhibit apoptosis and promote proliferation HD-Treg, and promotes IL-10 secretion. Blood, 2018, 132, 5602-5602.	0.6	0
104	Study of TIM-3 in Pathogenesis of Myelodysplastic Syndrome. Blood, 2018, 132, 4388-4388.	0.6	0
105	Deep sequencing of whole genome exon in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2017, 92, E51-E53.	2.0	6
106	Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. International Journal of Clinical Oncology, 2017, 22, 585-592.	1.0	5
107	CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodelling in vivo in myeloma bone disease. International Journal of Oncology, 2017, 50, 631-639.	1.4	26
108	Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes. International Journal of Hematology, 2017, 106, 248-257.	0.7	16

#	Article	IF	CITATIONS
109	TRAIL in CD8+ T cells from patients with severe aplastic anemia. International Journal of Hematology, 2017, 106, 490-499.	0.7	7
110	Decreased TIM-3 expression of peripheral blood natural killer cells in patients with severe aplastic anemia. Cellular Immunology, 2017, 318, 17-22.	1.4	11
111	Transforming growth factor 15 increased in severe aplastic anemia patients. Hematology, 2017, 22, 548-553.	0.7	6
112	Paraneoplastic <scp>E</scp> vans syndrome in a patient with adenocarcinoma of the lung: <scp>A</scp> case report. Thoracic Cancer, 2017, 8, 57-60.	0.8	12
113	High serum levels of complements C3 and C4 as novel markers for myeloma bone disease. Annals of Hematology, 2017, 96, 331-333.	0.8	5
114	De-escalation empirical antibiotic therapy improved survival for patients with severe aplastic anemia treated with antithymocyte globulin. Medicine (United States), 2017, 96, e5905.	0.4	6
115	Screening novel autoantigens targeted by serum IgG autoantibodies in immunorelated pancytopenia by SEREX. International Journal of Hematology, 2017, 106, 622-630.	0.7	8
116	Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Clinical Drug Investigation, 2017, 37, 167-174.	1.1	6
117	Lower level of IL‑35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs test‑positive hemocytopenia. Molecular Medicine Reports, 2017, 17, 2973-2981.	1.1	8
118	Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria. Experimental and Therapeutic Medicine, 2017, 15, 2525-2532.	0.8	1
119	Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes. Oncology Letters, 2016, 11, 2347-2352.	0.8	12
120	Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease. Annals of Hematology, 2016, 95, 1099-1106.	0.8	6
121	Abnormal histone acetylation of CD8+ T cells in patients with severe aplastic anemia. International Journal of Hematology, 2016, 104, 540-547.	0.7	14
122	The dysfunction of platelets in paroxysmal nocturnal hemoglobinuria. Thrombosis Research, 2016, 148, 50-55.	0.8	5
123	A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes. Biomedicine and Pharmacotherapy, 2016, 83, 1032-1037.	2.5	38
124	Expression and function of hematopoiesis-stimulating factor receptors on the GPlâ^' and GPl+ hematopoietic stem cells of patients with paroxysmal nocturnal hemoglobinuria/aplastic anemia syndrome. Experimental and Therapeutic Medicine, 2016, 11, 1668-1672.	0.8	2
125	A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults. International Journal of Hematology, 2016, 104, 462-467.	0.7	8
126	Decreased TIM-3 Expression Level of Peripheral Blood Natural Killer Cells in Severe Aplastic Anemia. Blood, 2016, 128, 5078-5078.	0.6	0

#	Article	IF	CITATIONS
127	The Role of PKM2 in the Activation of Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. Blood, 2016, 128, 1497-1497.	0.6	1
128	Hodgkin's lymphoma associated with myelofibrosis: A case report. Oncology Letters, 2015, 10, 1551-1554.	0.8	4
129	IgG autoantibody subclasses altered in immuno-related hemocytopenia. Cellular Immunology, 2015, 294, 13-20.	1.4	10
130	Abnormal quantity and function of regulatory T cells in peripheral blood of patients with severe aplastic anemia. Cellular Immunology, 2015, 296, 95-105.	1.4	30
131	Decreased Tim-3 Expression Level of Peripheral Blood Natural Killer Cells in Severe Aplastic Anemia. Blood, 2015, 126, 4767-4767.	0.6	Ο
132	Zoledronic Acid Inhibits Cell Growth of Multiple Myeloma Cells and Shows Synergistic Antimyeloma Effects with Bortezomib Via CD38 /cADPR /Ca2+ /Ras /Pakt /NF-Kb /Pim-2 Pathway. Blood, 2015, 126, 5311-5311.	0.6	1
133	Expression of Activated Molecules on CD5+ b Cells in Autoimmune Hemolytic Anemia. Blood, 2015, 126, 4765-4765.	0.6	Ο
134	Erythroblastic Islands in the Bone Marrow of Patients with Immune-Related Pancytopenia. PLoS ONE, 2014, 9, e95143.	1.1	12
135	Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell International, 2014, 14, 132.	1.8	31
136	Elevated TIM3+ hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis. Leukemia Research, 2014, 38, 714-721.	0.4	21
137	Increased Population Of Myeloid-Derived Suppressor Cells In Patients With Myelodysplastic Syndromes Overexpress ARG1 and Mediate CD8+ T Cell Inhibition. Blood, 2013, 122, 5212-5212.	0.6	1
138	The Study Of The Effect and Mechanism Of Chemotherapy Plus Granulocyte Colony Stimulating Factor (DAG) for Refractory Paroxysmal Nocturnal Hemoglobinuria In Vitro. Blood, 2013, 122, 4717-4717.	0.6	0
139	Abnormal Expression Of Shelterin Is Associated With Short Telomere and Immune Disorder In Severe Aplastic Anemia. Blood, 2013, 122, 5562-5562.	0.6	0
140	The Mechanisms Of Damage To Bone Marrow By Iron Overload In Patients With Immuno-Related Pancytopenia. Blood, 2013, 122, 5561-5561.	0.6	0
141	Vitro Culture and Regulation Of Osteoblasts and Cellular Immunity Function In Multiple Myeloma patients. Blood, 2013, 122, 5329-5329.	0.6	0
142	Recombinant Human Thrombopoietin Promotes The Recovery Of Megakaryocyte Lineage In Patients With Severe Aplastic Anemia Receiving Immunosuppressive Therapy. Blood, 2013, 122, 2437-2437.	0.6	0
143	CD8+HLA-DR+ T Cells Are Increased in Patients with Severe Aplastic Anemia. Blood, 2012, 120, 4395-4395.	0.6	2
144	The Expressions of CD114, CD117 and STAT5 in CD34+CD59â^ and CD34+CD59+ Bone Marrow Cells of the Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2012, 120, 4404-4404.	0.6	0

#	Article	IF	CITATIONS
145	TET2 Gene Expression in Bone Marrow Cells in Myelodysplastic Syndromes Patients and the Effect of Silencing TET2 by siRNA On Biological Characteristics of Healthy CD34+ Cells. Blood, 2012, 120, 4934-4934.	0.6	1
146	Expression and Clinical Significance of Notch1 On the Membrane of Bone Marrow CD38+CD138+Plasma Cells in the Patients with Multiple Myeloma. Blood, 2012, 120, 4981-4981.	0.6	0
147	Expression of dlk1 in the Bone Marrow Cells of Patients with Myelodysplastic Syndrome and Its Clinical Significance. Blood, 2011, 118, 5042-5042.	0.6	0
148	Preliminary Study of the Autoantigens on the Membrane of Erythropoietic Cells of the Patients with BMMNC- Coomb's Test(+) Hemocytopenia. Blood, 2011, 118, 4382-4382.	0.6	0
149	The Somatic Mutation of PIG-A Gene and the Expressions of EGR-1 and WT1 Genes in Bone Marrow Cells of the Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2011, 118, 4379-4379.	0.6	0
150	Chemotherapy Plus Hematopoietic Growth Factor for Refractory Paroxysmal Nocturnal Hemoglobinuria: Diminishing PNH Clone and Stimulating Hematopoisis. Blood, 2011, 118, 4376-4376.	0.6	0
151	Study on the Pathways to Damage Hematopoiesis by CD8+ Effector T Cells of the Patients with Severe Aplastic Anemia. Blood, 2011, 118, 4371-4371.	0.6	0
152	TET2 mRNA Expression in Bone Marrow Mononuclear Cells of the Patients with Myelodysplastic Syndromes and it's Clinical Significances. Blood, 2011, 118, 5036-5036.	0.6	0
153	Study on the Quantities and Functions of Natural Killer Cell Subsets in Peripheral Blood of the Patients with Severe Aplastic Anemia,. Blood, 2011, 118, 3423-3423.	0.6	0
154	Preliminary Study of the Relationship Between EPO Receptor and Autoantibody on the Membrane of Erythropoietic Cells of the Patients with BMMNC- Coomb's Test(+) Hemocytopenia. Blood, 2010, 116, 4436-4436.	0.6	8
155	Expression of CD123 and CD114 on the Bone Marrow Cells of Patients with Myelodysplastic Syndromes. Blood, 2010, 116, 4966-4966.	0.6	0
156	Study of the Quantity and Function of Regulatory T Cells In the Hemocytopenic Patients with Positive BMMNC-Coombs Test. Blood, 2010, 116, 4875-4875.	0.6	1
157	Study on the Ratio and Function of Macrophages in the Patients with BMMNCCoombs Test(+) Hematocytopenia. Blood, 2008, 112, 4656-4656.	0.6	0
158	In Vitro Study of the Function of Dendritic Cells on Stimulating T Lymphocytes Proliferation in Severe Aplastic Anemia. Blood, 2008, 112, 4919-4919.	0.6	0
159	Study on the Mechanism of â€~ei'formation in the Bone Marrow Smears of the Patients with BMMNC-Coombs Test(+) Hematocytopenia. Blood, 2008, 112, 4753-4753.	0.6	0
160	Study on the Dendritic Cell Subsets and Their Relationship with the Expressions of T-Bet and GATA-3 in Peripheral Lymphocytes of Severe Aplastic Anemia Patients. Blood, 2008, 112, 4901-4901.	0.6	1
161	The Expression and Clinical Significance of PRAME Gene in Acute Leukemia Blood, 2007, 110, 4225-4225.	0.6	1
162	An Analysis of Occurrence and Prognosis Related Factors of Renal Dysfunction in Patients with Multiple Myeloma Blood, 2007, 110, 4732-4732.	0.6	0

#	Article	IF	CITATIONS
163	Role of B lymphocyte and its subpopulations in pathogenesis of immunorelated pancytopenia. Chinese Medical Sciences Journal, 2007, 22, 199-202.	0.2	5
164	The Auto-Antibodies on Bone Marrow Cells in the Patients with Systemic Lupus Erythematosus Blood, 2006, 108, 3856-3856.	0.6	0
165	Proliferative Function of Bone Marrow Hematopoietic Stem Cells of Patients with Systemic Lupus Erythematosus Blood, 2006, 108, 3857-3857.	0.6	0
166	Gene therapy with B ell maturation antigen/ <scp>CD3</scp> bispecific antibody encoding plasmid <scp>DNA</scp> for treating multiple myeloma. British Journal of Haematology, 0, , .	1.2	0